Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Stryker (SYK) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scor ...

Aster Capital Management DIFC Ltd cut its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 44.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,491 shares of the medical technology company’s stock after selling 2,779 shares during the quarter. Stryker makes up about 0.7% of Aster Capital Management DIFC Ltd’s portfolio, making the stock its 28th largest position. Aster Capital Mana ...

With a market cap of around $147 billion, Stryker Corporation (SYK) is a global medical technology company that develops and markets innovative products for use by doctors, hospitals, and healthcare facilities across approximately 61 countries. It operates primarily through its MedSurg and Neurotechnology, and Orthopaedics segments, offering solutions ranging from surgical equipment and AI-assisted virtual care to stroke treatment and patient safety technologies. Companies valued at $10 billion or more a ...

Key Takeaways Stryker launched Synchfix EVT, a next-gen flexible fixation system for ankle syndesmotic injuries.SYK's device simplifies deployment, supports single-handed use and improves OR efficiency.Stryker's system is first approved for adolescents, expanding reach in ankle trauma care.Stryker (SYK) recently expanded its trauma portfolio with the launch of Synchfix EVT, a next-generation flexible syndesmotic fixation system to improve procedural efficiency and maintain effective ankle stabilization in p ...

Stryker launches Synchfixâ"¢ EVT, expanding options for flexible syndesmotic fixation [Accessibility Statement] Skip NavigationElevating care with Stryker's next generation device, [Synchfix EVT], which will be featured at the 2026 American College of Foot and Ankle Surgeons (ACFAS) Annual MeetingPORTAGE, Mich., Feb. 24, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of Synchfixâ"¢ EVT, its next-generation flexible syndesmotic fixation device designed ...

Stryker Corporation (NYSE:SYK) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 2, the price target on Stryker Corporation (NYSE:SYK) was raised from $462 to $469 by Barclays. The firm reaffirmed its Overweight rating on the stock that yields a revised upside potential of more than 23%. Without any deviations from the model, the firm believes there is significant upside for the company’s growth estimates for 2026. Stryker Corporation (SYK) Gains Strength From ...

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Core Insights - Stryker (SYK) has launched the T2 Alpha Humerus Nailing System, aimed at simplifying surgical procedures for humeral fracture fixation and enhancing patient care consistency [1][4]. Product Overview - The T2 Alpha Humerus Nailing System improves surgeons' management of complex humeral fractures by providing increased procedural flexibility and builds on Stryker's collaboration with surgeons [2][4]. - The system utilizes Stryker's SOMA technology to manage complex fractures, including non-unions and malunions, featuring an anatomically informed nail design for better alignment and fixation stability [7][10]. - It allows for active intraoperative compression of up to 6 mm for controlled fracture reduction and offers multiplanar screw fixation for enhanced stability [11]. Market Performance - Following the announcement of the new system, SYK shares increased by 0.7%, although the stock has seen a 3.4% decline over the past six months, contrasting with an 11.6% decline in the industry and a 9.8% rise in the S&P 500 during the same period [3]. Long-term Outlook - The launch is expected to strengthen Stryker's trauma and orthopedics portfolio, potentially leading to increased procedure volumes and sustained demand in hospital settings, thereby supporting revenue growth and competitive differentiation in the orthopedic trauma market [4][9]. - The trauma and extremities devices market is projected to reach $16.55 billion by 2026, with a CAGR of 5.2% through 2034, driven by the rising prevalence of orthopedic disorders and advancements in less invasive surgical techniques [12].

Core Viewpoint - GE HealthCare Technologies (GEHC) is currently viewed as a more attractive investment option compared to Stryker (SYK) for value investors, based on stronger earnings outlook and favorable valuation metrics [3][7]. Valuation Metrics - GEHC has a forward P/E ratio of 15.89, significantly lower than SYK's forward P/E of 24.22, indicating that GEHC may be undervalued [5]. - The PEG ratio for GEHC is 1.75, while SYK's PEG ratio stands at 2.11, suggesting that GEHC offers better value relative to its expected earnings growth [5]. - GEHC's P/B ratio is 3.47, compared to SYK's P/B of 6.16, further supporting the notion that GEHC is more attractively priced [6]. Investment Ratings - GEHC holds a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while SYK has a Zacks Rank of 3 (Hold) [3]. - Based on the overall valuation metrics, GEHC has a Value grade of A, whereas SYK has a Value grade of C, reinforcing the preference for GEHC among value investors [6].

Financial Performance - Stryker achieved reported net sales growth of 11.2% in 2025, with net sales totaling $25,116 million[141] - Adjusted net earnings per diluted share increased by 11.8% to $13.63, with net earnings reaching $3,246 million[141] - Net earnings for 2025 increased to $3,246 million or $8.40 per diluted share from $2,993 million or $7.76 per diluted share in 2024[173] - Operating income increased to $4,889 million in 2025, with an operating income margin of 19.5%[163] - Gross profit for 2025 was $16,065 million, up from $14,440 million in 2024, reflecting a gross margin improvement[247] - Net earnings for 2025 were $3,246 million, compared to $2,993 million in 2024, representing an 8.5% growth[247] Sales Growth - MedSurg and Neurotechnology net sales grew by 15.7% as reported, totaling $15,647 million, with a 10.0% increase in constant currency excluding acquisitions[150] - Orthopaedics segment net sales increased by 4.3% to $9,469 million, with a 3.8% increase in constant currency[147] - The United States market contributed $19,006 million in sales, reflecting a 12.2% increase, while international sales reached $6,110 million, an 8.1% increase[147] - MedSurg and Neurotechnology net sales in 2024 increased by 11.1% as reported and 11.6% in constant currency, with a 0.5% negative impact from foreign currency exchange rates[151] - Orthopaedics net sales in 2025 increased by 4.3% as reported and 3.8% in constant currency, with a 0.5% positive impact from foreign currency exchange rates[152] Expenses and Costs - Research, development, and engineering expenses rose to $1,623 million, representing 6.5% of net sales[147] - Selling, general and administrative expenses as a percentage of net sales increased to 34.4% in 2025 from 34.0% in 2024, driven by higher acquisition-related costs[158] - Interest expense increased by 48.4% to $607 million, impacting overall profitability[147] - Cash paid for income taxes in 2025 was $1,002 million, compared to $989 million in 2024, showing a slight increase of 1.3%[260] Capital Allocation and Investments - The company invested $4,960 million in acquisitions and paid $1,284 million in dividends to shareholders in 2025[142] - Stryker's capital allocation strategy continues to prioritize acquisitions, dividends, and share repurchases to drive long-term growth[141] - Cash used in investing activities was $4,866 million in 2025, primarily for the acquisition of Inari and purchases of property, plant, and equipment[191] - Total dividends paid to common shareholders increased to $1,284 million in 2025 from $1,219 million in 2024, with dividends per share rising to $3.36[194] Tax and Impairments - The effective tax rate was 28.1% in 2025, an increase from 14.3% in 2024, influenced by tax effects from intellectual property transfers[171] - Goodwill and other impairments recorded were $170 million in 2025, with significant impairments related to the Spine business in 2024[161] - Adjustments to income taxes for 2025 included a charge of $660 million related to the transfer of intellectual properties between tax jurisdictions[202] - An impairment charge of $273 million was recognized for the Spine reporting unit due to decreased future product demand and increased weighted average cost of capital[221] Liquidity and Financial Position - The company maintained a strong liquidity position with cash, cash equivalents, and marketable securities totaling $4,100 million as of December 31, 2025[195] - Total assets increased to $47,844 million in 2025 from $42,971 million in 2024, representing a growth of 6.5%[251] - Cash and cash equivalents rose to $4,011 million in 2025, compared to $3,652 million in 2024, marking an increase of 9.8%[258] - Long-term debt, excluding current maturities, increased to $14,859 million in 2025 from $12,188 million in 2024, an increase of 21.9%[251] Accounting and Reporting - The company is evaluating the impact of new accounting standards issued by the FASB, including ASU 2025-10 and ASU 2025-07, on its consolidated financial statements[308][309] - The company adopted ASU 2023-09 for income tax disclosures effective January 1, 2025, which may impact future financial reporting[314] - The company performed a quantitative impairment test for goodwill, indicating that the implied fair values of other reporting units exceed their carrying amounts by at least 100%[227] Currency and Derivatives - A hypothetical 10% change in foreign currencies relative to the U.S. Dollar would change the fair value of derivative instruments by approximately $449 million[239] - The company recognized $25 million in cash flow hedges related to cost of sales for 2025, down from $31 million in 2024[335] - The total fair value of cash flow hedges was $148 million, with $15 million in other current assets and ($70) million in other current liabilities[334]